

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

01-04-01

A
Box
Sequ

01/03/01

UTILITY PATENT APPLICATION TRANSMITTAL <small>(Only for new nonprovisional applications under 37 C.F.R. 1.53(b))</small>	Attorney Docket No.	2891.1001-026
	First Named Inventor or Application Identifier	Marc Feldmann
	Express Mail Label No.	EL552578549US

Title of Invention	TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE
-----------------------	--

<p style="text-align: center;">APPLICATION ELEMENTS</p> <p>See MPEP chapter 600 concerning utility patent application contents.</p> <p>1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification Total Pages 57 <i>(preferred arrangement set forth below)</i></p> <ul style="list-style-type: none"> - Descriptive title of the invention - Cross References to Related Applications - Statement Regarding Fed sponsored R & D - Reference to microfiche Appendix - Background of the Invention - Summary of the Invention - Brief Description of the Drawings - Detailed Description - Claim(s) - Abstract of the Disclosure <p>3. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) Total Sheets 8 <input checked="" type="checkbox"/> Formal <input type="checkbox"/> Informal <input type="checkbox"/> Fig. of the Drawings for Publication <input type="checkbox"/> None]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration/POA Total Pages 3</p> <p style="margin-left: 20px;">a. <input type="checkbox"/> Newly executed (original or copy)</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> Copy from a prior application (37 C.F.R. 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> [NOTE Box 5 below]</p> <p style="margin-left: 40px;">i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).</p> <p>5. <input checked="" type="checkbox"/> Incorporation By Reference <i>(useable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein</p>	<p>ADDRESS TO: Assistant Commissioner for Patents Box Patent Application Washington, D.C. 20231</p> <p>6. <input type="checkbox"/> Microfiche Computer Program <i>(Appendix)</i></p> <p>7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i></p> <p style="margin-left: 20px;">a. <input checked="" type="checkbox"/> Computer Readable Copy</p> <p style="margin-left: 20px;">b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) 1 Page</p> <p style="margin-left: 20px;">c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p>
--	--

ACCOMPANYING APPLICATION PARTS
<p>8. <input type="checkbox"/> Assignment Papers (cover sheet & documents) <input checked="" type="checkbox"/> Assignee - The Kennedy Institute of Rheumatology, England</p> <p>9. <input type="checkbox"/> 37 C.F.R. 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>10. <input type="checkbox"/> English Translation Document <i>(if applicable)</i></p> <p>11. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity Statement(s) <input type="checkbox"/> Statement filed in prior application, status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> <p>16. <input type="checkbox"/> Nonpublication Request <i>(check parent application)</i></p> <p>17. <input checked="" type="checkbox"/> Other: <u>Remarks</u></p>

18.	If a CONTINUING APPLICATION , check appropriate box and supply the requisite information:	
	<input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP)	of prior application No.: 08/690,775
	Prior application information: Examiner: P. Gambel	Group Art Unit: 1644

19. CORRESPONDENCE ADDRESS					
NAME	David E. Brook, Esq.				
	HAMILTON, BROOK, SMITH & REYNOLDS, P.C.				
ADDRESS	Two Militia Drive				
CITY	Lexington	STATE	MA	ZIP CODE	02421-4799
COUNTRY	USA	TELEPHONE	(781) 861-6240	FAX	(781) 861-9540

Signature		Date	January 3, 2001
Submitted by Typed or Printed Name	Helen Lee	Reg. Number	39,270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Continuation Application of

Application No.: 08/690,775

Filed: August 1, 1996

For: TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF
TNF-MEDIATED DISEASE



Date: <u>1-3-01</u>
EXPRESS MAIL LABEL NO. <u>EL 552578549US</u>

REMARKS

Box PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The above-captioned application is a continuation of application number 08/690,775 ('775) filed on August 1, 1996 to which priority is claimed under 35 U.S.C. § 120.

The specification has been revised to incorporate amendments entered in the '775 application. The specification has also been revised to remove underlining and bolding of text. In certain instances, underlining has been replaced with capitalization. The specification has been amended to provide the U.S. Patent Numbers for the cited U.S. applications which have matured into patents. The related applications paragraph has been revised to include the '775 application.

The sequence listing has been amended to comply with Sequence Rules 37 C.F.R. §§ 1.821-1.825, as revised on July 1, 1998. More specifically, the sequence listing has been amended to include the docket number for the referenced application, the '775 application in the prior application data and the organism information, and to delete the correspondence address, attorney/agent information and telecommunication information. The sequence listing has also

been revised to include the amended title of the invention (see below). No new matter has been added.


Claims 1-30 of the '775 application have been omitted and remaining Claim 31 has been renumbered as Claim 1. Presently numbered Claims 2-38 have been added as new claims to the above-captioned application. Support for presently numbered Claims 2-38 can be found throughout the specification including, for example, at page 6, lines 10-15; page 8, line 22 to page 8, line 9; page 9, line 18 to page 15, line 3; and page 23, line 18 to page 25, line 7 (which correspond to page 8, lines 6-14; page 8, line 25 to page 10, line 35; page 12, line 30 to page 20, line 23; and page 32, line 30 to page 35, line 11 of the '775 application).

The title of the invention has been amended to "TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF TNF-MEDIATED DISEASE" to more specifically correspond to the claimed subject matter.

Formal drawings (8 sheets consisting of Figures 1A-1C, 2A-2C, 3A-3C, 4A-4C, 5A-5C, 6A-6C, 7A-7F and 8A-8B) have been submitted with the above-captioned application.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 
Helen Lee
Registration No. 39,270
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *January 3, 2001*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Marc Feldmann and Ravinder N. Maini

Continuation Application of

Application No.: 08/690,775

Filed: August 1, 1996

For: TNF α ANTAGONISTS AND METHOTREXATE IN THE TREATMENT OF
TNF-MEDIATED DISEASE

Date: <u>1-3-01</u>
EXPRESS MAIL LABEL NO. <u>EL55257854905</u>

TRANSMITTAL OF SEQUENCE LISTING IN COMPUTER READABLE FORM
IN COMPLIANCE WITH 37 C.F.R. §§ 1.821(e) AND (f)

Box Sequence
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. § 1.821(e). As required by 37 C.F.R. § 1.821(f), Applicants' Attorney hereby states that the content of the "Sequence Listing" in paper form and of the computer readable form of the "Sequence Listing" are the same.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Helen Lee
Helen Lee
Registration No. 39,270
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Date: January 3, 2001

SEQUENCE LISTING

<110> Marc Feldmann
Ravinder N. Maini

<120> TNF Alpha Antagonists and Methotrexate
in the Treatment of TNF-Mediated Disease

<130> 2891.1001-026

<150> 08/690,775

<151> 1996-08-01

<150> 08/607,419

<151> 1996-02-28

<150> PCT/GB94/00462

<151> 1994-03-10

<150> PCT/GB93/02070

<151> 1993-10-06

<150> 07/958,248

<151> 1992-10-08

<160> 2

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 16

<212> PRT

<213> Homo sapien

<400> 1

Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Ser Thr His Val
1 5 10 15

<210> 2

<211> 22

<212> PRT

<213> Homo sapien

<400> 2

Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala Ile Lys Ser Pro Cys Gln
1 5 10 15
Arg Glu Thr Pro Glu Gly
20

2891.1001-026